Arcus Biosciences, Inc. reported significant financial developments in its latest 10-Q filing for the three and nine months ended September 30, 2024. The company achieved total revenues of $48 million for the third quarter, a 50% increase from $32 million in the same period of 2023. For the nine months, revenues surged to $232 million, up 170% from $86 million year-over-year. This growth was primarily driven by increased revenue from collaboration agreements, particularly with Gilead and Taiho Pharmaceutical.
Operating expenses for the third quarter rose to $153 million, compared to $112 million in the prior year, reflecting a 37% increase. For the nine months, operating expenses totaled $459 million, up from $335 million in 2023. The loss from operations for the third quarter was $(105) million, worsening from $(80) million in 2023, while the nine-month loss from operations decreased to $(227) million from $(249) million in the previous year. The net loss for the third quarter was $(92) million, compared to $(71) million in 2023, but the nine-month net loss improved to $(189) million from $(226) million.
As of September 30, 2024, Arcus reported total current assets of $1,127 million, up from $831 million at the end of 2023. The company held cash and cash equivalents of $201 million and marketable securities of $888 million. Total assets increased to $1,252 million, with stockholders' equity rising to $565 million from $462 million at the end of 2023. However, the accumulated deficit grew to $(1,038) million from $(849) million.
Strategically, Arcus has strengthened its collaboration with Gilead, which now holds approximately 32.9% of the company's outstanding common stock. Gilead's investments included a $320 million purchase of 15.2 million shares in January 2024. The collaboration has been pivotal, with Gilead accounting for 89% of total revenues for the nine months ended September 30, 2024.
The company also entered into a loan agreement with Hercules Capital for up to $250 million, with $50 million drawn at closing. This financing is expected to support ongoing operations, which are projected to be funded into mid-2027.
Overall, while Arcus continues to incur substantial losses, its revenue growth and strategic partnerships position it for potential future success in the biopharmaceutical sector.
About Arcus Biosciences, Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.